Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Firsekibart, an Anti-interleukin-1β Monoclonal Antibody, in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Adv Ther · 2025 · PMC12394284 · PMID 40711661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Although the relationship between dose and C max or AUC 0– t could not be definitively established, a clear trend of linear PK profile between 0.3 and 6 mg/kg was observed (Supplementary Material, Table S1 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.